There is a version of competitive intelligence that feels rigorous but isn’t. It lives in MSL field reports, physician advisory boards, and HCP surveys — all legitimate sources, all useful for understanding what prescribers observe and believe. None of them tell you what patients are actually doing when they consider switching, start researching alternatives, or quietly disengage from a therapy they’ve stopped trusting.
That gap between what physicians report and what patients experience is where brand share gets lost.
How brands get the wrong signal
The standard competitive intelligence workflow runs roughly like this: field teams report what physicians say patients are asking about; advisory boards surface what KOLs believe drives treatment decisions; brand trackers measure awareness and intent at the HCP level. The patient is present in that data only as a secondhand account — filtered through a clinical relationship, a visit that lasted twelve minutes, and a physician’s interpretation of what a patient meant when they said they were “thinking about trying something different.”
That interpretation is often wrong.
In a structured patient insights study Inspire conducted for a biopharmaceutical company developing a treatment for Chronic Spontaneous Urticaria, the medical and commercial teams shared a well-established belief: patients were less concerned about neutropenia than physicians assumed, and more focused on aesthetic side effects like hair color changes. That belief was shaping patient education materials, MSL talking points, and how the safety profile was being communicated across the brand.
The patient data said the opposite. Patients ranked neutropenia as their primary concern — directly contradicting the prevailing assumption that had been guiding strategy. The team had been calibrating messaging around the wrong hierarchy of risk, a gap that had real implications for informed consent conversations, patient confidence, and brand trust.
The assumption didn’t come from negligence. It came from a research design that asked physicians what patients thought instead of asking patients directly.
Where switching actually happens
Physician reports of patient switching tend to cluster around clinical moments: efficacy failures, adverse events, formulary changes. Those are real drivers. They are not the whole story.
Patients describe a different and more gradual process. Switching behavior in patient communities tends to begin long before a clinical trigger — in conversations with other patients about what their experience has been, in online research conducted between appointments, in the accumulating weight of small frustrations that never quite rise to the level of something worth mentioning to a doctor.
In an ATU study Inspire conducted for a pharmaceutical company navigating a shift in standard of care for a rare cancer, the data revealed how dramatically patient priorities and information-seeking behavior changed across the treatment journey. At diagnosis, patients relied heavily on oncologists and patient organizations, and efficacy was the dominant concern. By the time of relapse, fifty percent of patients had turned to family and friends as primary sources of information, and forty to fifty percent were actively discussing alternative treatments with their physicians — often after having already formed an opinion.
The brand had touchpoints mapped to the clinical journey. It did not have touchpoints mapped to where patients were actually making decisions. The gaps between those two maps were where patients were disengaging, encountering misinformation, and being influenced by competing narratives the brand wasn’t part of.
The compounding problem of assumed loyalty
Mature brands face a specific version of this problem. Patients who have been on therapy for an extended period are often treated as retained — they’re not actively considering a switch, so competitive intelligence efforts focus elsewhere. What that assumption misses is the difference between patients who are satisfied and patients who are staying because switching feels complicated.
Those two groups look identical in claims data. They don’t behave identically when a new option enters the market, a peer in their online community shares a negative experience, or a coverage change introduces friction into their existing regimen.
The patients most at risk of switching are often not the ones your field teams are hearing about.
What direct patient research surfaces that indirect research can't
The distinction isn’t simply about asking patients instead of physicians. It’s about research design that captures unprompted behavior — what patients say when they’re not being asked about your brand specifically, what language they use when describing dissatisfaction, what the actual sequence of events looks like in the period before a switch occurs.
Inspire’s 3 million members across 250+ disease communities generate that signal continuously. The patients discussing treatment alternatives in a rare cancer community today are not waiting for a brand survey to express their concerns. They are already describing their decision-making process, naming the factors that matter to them, and influencing the patients around them.
Structured competitive intelligence studies built on that foundation — switching driver analysis, competitive perception surveys, patient journey mapping at the moment of treatment change — produce findings that field teams can actually use. Not because they confirm what the brand already believes, but precisely because they don’t.
The right question for brand teams
The brands that defend share most effectively in competitive markets are the ones that know what patients think before a competitor’s launch forces the question. That means running the research when things are stable, not when they’re already moving.
If your current competitive intelligence picture comes primarily from physician-reported patient behavior, it is telling you what patients said in a clinical setting, filtered through a clinician’s interpretation, aggregated into a field report. That is not the same as knowing what patients think.
The gap between those two things is worth understanding before a competitor does it for you.